Serum microRNAs are promising novel biomarkers. PLoS ONE 3(9):e3148

Texas Tech University Health Sciences Center, United States of America
PLoS ONE (Impact Factor: 3.23). 02/2008; 3(9):e3148. DOI: 10.1371/journal.pone.0003148
Source: PubMed

ABSTRACT Circulating nucleic acids (CNAs) offer unique opportunities for early diagnosis of clinical conditions. Here we show that microRNAs, a family of small non-coding regulatory RNAs involved in human development and pathology, are present in bodily fluids and represent new effective biomarkers.
After developing protocols for extracting and quantifying microRNAs in serum and other body fluids, the serum microRNA profiles of several healthy individuals were determined and found to be similar, validating the robustness of our methods. To address the possibility that the abundance of specific microRNAs might change during physiological or pathological conditions, serum microRNA levels in pregnant and non pregnant women were compared. In sera from pregnant women, microRNAs associated with human placenta were significantly elevated and their levels correlated with pregnancy stage.
Considering the central role of microRNAs in development and disease, our results highlight the medically relevant potential of determining microRNA levels in serum and other body fluids. Thus, microRNAs are a new class of CNAs that promise to serve as useful clinical biomarkers.

Download full-text


Available from: Zvi Bentwich, Sep 02, 2015
1 Follower
  • Source
    • "The stability of miRNAs was demonstrated using sera from various sources, after treatment under harsh conditions including boiling, low/high pH, extended storage and freeze–thaw cycles. The detection of miRNAs in serum samples treated under these harsh conditions yielded no significant differences compared to nontreated serum (Chen et al. 2008; Gilad et al. 2008; Mitchell et al. 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The selection of biomarkers in nutrigenomics needs to reflect subtle changes in homoeostasis representing the relation between nutrition and health, or nutrition and disease. It is believed that noncoding RNAs, such as circulating microRNAs (miRNAs), may represent such a new class of integrative biomarkers. Until now, the most relevant body fluids for miRNA quantification in response to nutrition have not been clearly defined, but recent studies listed in this review indicate that miRNAs from plasma or serum, PBMC and faeces might be relevant biomarkers to quantify the physiological impacts of dietary or lifestyle intervention studies. In addition, a number of recent studies also indicate that miRNAs could permit to monitor the impact of diet on gut microbiota. We also discuss the main preanalytical considerations that are important to take into account before miRNA screening which can affect the reproducibility of the data.
    Genes & Nutrition 09/2015; 10(5):483. DOI:10.1007/s12263-015-0483-1 · 3.42 Impact Factor
  • Source
    • "MiR-143 which has a role in the adult adipose tissue related with obesity is a well known miRNA (Yi et al., 2011). It has been demonstrated that the levels of miRNAS are remarkably stable and reproducible (Gilad et al., 2008). These findings aroused interest in the use of miRNAs as biomarkers in different clinical settings. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity alters endocrine and metabolic functions of adipose tissue and has been recognized as a chronic inflammatory disease, which in turn may contribute to the development of insulin resistance, type 2 diabetes, obesity-associated vasculopathy and cardiovascular disease. The pathogenesis of obesity involves many regulatory pathways including transcriptional regulatory networks, including microRNAs. A total of 83 patients were included in the study. Patients were recruited from a cardiology outpatient clinic and were allocated into 3 age- and sex-matched groups according to their body mass index. Group 1 included 23 morbidly obese, group 2 30 obese, and group 3 30 normal or overweight subjects. In our study, we showed that miR-143 and miR-223 levels were significantly lower in groups 1 and 2 than the control group (normal BMI or overweight). Obesity leads to alterations in miRNA expressions and miRNA-143 and -223s can be used as biomarkers for the metabolic changes in obesity. Copyright © 2015. Published by Elsevier B.V.
    Gene 01/2015; 560(2). DOI:10.1016/j.gene.2015.01.048 · 2.08 Impact Factor
  • Source
    • "However, most of these studies have been performed on ovarian tissue samples. Recent studies have demonstrated that microRNAs are circulating freely in serum and other body fluids in a highly stable, cell-free form [22] [23] [24] [25] [26] [27] [28] [29]. Circulating microRNAs are highly tissue specific and can identify origin of metastasis and can be used as noninvasive biomarkers for cancers [22] [23] [30]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian cancer is the seventh most common cancer in women and the most frequent cause of gynaecological malignancy-related mortality in women. Currently, no standardized reliable screening test exists. MicroRNA profiling has allowed the identification of signatures associated with diagnosis, prognosis and response to treatment of human tumours. The aim of this study was to determine if a microRNA signature could distinguish between malignant and benign ovarian disease. A training set of 5 serous ovarian carcinomas and 5 benign serous cystadenomas were selected for the initial experiments. The validation set included 20 serous ovarian carcinomas and 20 benign serous cystadenomas. The serum/plasma focus microRNA Exiqon panel was used for the training set. For the validation set a pick and mix Exiqon panel, which focuses on microRNAs of interest was used. A panel of 4 microRNAs (let-7i-5p, miR-122, miR-152-5p and miR-25-3p) was significantly down regulated in cancer patients. These microRNAs target WNT signalling, AKT/mTOR and TLR-4/MyD88, which have previously been found to play a role in ovarian carcinogenesis and chemoresistance. let-7i-5p, miR-122, miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer.
    Cancer letters 10/2014; 356(2). DOI:10.1016/j.canlet.2014.10.010 · 5.62 Impact Factor
Show more